We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Did AbbVie's Neuroscience Franchise Perform in Q3?
Read MoreHide Full Article
Key Takeaways
AbbVie's neuroscience revenues rose 19.5% operationally to $3.39 billion, contributing 19.5% of total sales.
Vraylar, Botox, Ubrelvy and Qulipta drove growth, with Qulipta sales rising 38.5% year over year.
AbbVie raised its 2026 neuroscience sales forecast to $13 billion, up from its prior $12.7 billion outlook.
AbbVie’s (ABBV - Free Report) neuroscience segment delivered encouraging sales growth in the third quarter of 2026, which exceeded our consensus estimates. The franchise continues to post double-digit growth, with its contribution to the company’s overall top line steadily increasing — a trend that remained evident in the reported quarter.
AbbVie's neuroscience franchise generated $3.39 billion in revenues during the third quarter, accounting for approximately 19.5% of its total revenues. The segment is AbbVie's second-largest revenue contributor after immunology.
Sales rose 19.5% year over year on an operational basis. The growth was broad-based, with all three key therapeutic areas, psychiatry, migraine and Parkinson’s disease (PD), contributing to the performance.
A Closer Look at ABBV’s Neuroscience Drugs
Vraylar remained the largest contributor, generating $1.07 billion in sales during the third quarter, up 14.3% year over year. Per AbbVie, the drug continued to benefit from share gains across its approved indications, namely bipolar disorder and adjunctive major depressive disorder.
AbbVie’s migraine portfolio was another source of growth. Ubrelvy sales rose 26.9% year over year to $449 million, while Qulipta generated revenues of $398 million, up 38.5%. Botox Therapeutic sales increased 9.8% to $1.08 billion.
The PD drug Vyalev generated $286 million in sales, up 11.7% on a sequential basis.
ABBV Raises 2026 Neuroscience Sales Outlook
Continued strength in its neuroscience franchise prompted AbbVie to raise its 2026 sales outlook to about $13 billion, up from the prior expectation of $12.7 billion.
Sales of both Vraylar and Botox Therapeutics are now expected to be $4.2 billion each. Combined sales of Ubrelvy and Qulipta are expected to be around $3.1 billion.
Management reiterated that Vyalev remains on track to achieve blockbuster status this year, reflecting the drug’s accelerated uptake.
Regarding the newly approved PD drug Juvmo, AbbVie said it represents a sizable commercial opportunity. However, sales are expected to ramp up gradually as commercial insurance and Medicare coverage expands, particularly from 2028.
Overall, AbbVie raised its 2026 revenue outlook by $200 million to approximately $67.8 billion.
ABBV’s Competition in the Neuroscience Space
Other major players in the neuroscience space include Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .
With revenues from its legacy multiple sclerosis portfolio continuing to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for Alzheimer's disease. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.
J&J's neuroscience business is anchored by the blockbuster depression therapy Spravato and long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year bolstered its portfolio with Caplyta, an approved treatment for schizophrenia and bipolar depression.
ABBV’s Price Performance, Valuation and Estimates
Year to date, shares of AbbVie have risen 29% compared with the industry’s nearly 27% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a slight discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 18.67 times forward earnings, lower than its industry’s average of 19.88 times.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2026 has risen slightly from $13.96 to $13.97, while the 2027 estimate has increased from $15.95 to $16.02 over the past 30 days.
Image: Bigstock
How Did AbbVie's Neuroscience Franchise Perform in Q3?
Key Takeaways
AbbVie’s (ABBV - Free Report) neuroscience segment delivered encouraging sales growth in the third quarter of 2026, which exceeded our consensus estimates. The franchise continues to post double-digit growth, with its contribution to the company’s overall top line steadily increasing — a trend that remained evident in the reported quarter.
AbbVie's neuroscience franchise generated $3.39 billion in revenues during the third quarter, accounting for approximately 19.5% of its total revenues. The segment is AbbVie's second-largest revenue contributor after immunology.
Sales rose 19.5% year over year on an operational basis. The growth was broad-based, with all three key therapeutic areas, psychiatry, migraine and Parkinson’s disease (PD), contributing to the performance.
A Closer Look at ABBV’s Neuroscience Drugs
Vraylar remained the largest contributor, generating $1.07 billion in sales during the third quarter, up 14.3% year over year. Per AbbVie, the drug continued to benefit from share gains across its approved indications, namely bipolar disorder and adjunctive major depressive disorder.
AbbVie’s migraine portfolio was another source of growth. Ubrelvy sales rose 26.9% year over year to $449 million, while Qulipta generated revenues of $398 million, up 38.5%. Botox Therapeutic sales increased 9.8% to $1.08 billion.
The PD drug Vyalev generated $286 million in sales, up 11.7% on a sequential basis.
ABBV Raises 2026 Neuroscience Sales Outlook
Continued strength in its neuroscience franchise prompted AbbVie to raise its 2026 sales outlook to about $13 billion, up from the prior expectation of $12.7 billion.
Sales of both Vraylar and Botox Therapeutics are now expected to be $4.2 billion each. Combined sales of Ubrelvy and Qulipta are expected to be around $3.1 billion.
Management reiterated that Vyalev remains on track to achieve blockbuster status this year, reflecting the drug’s accelerated uptake.
Regarding the newly approved PD drug Juvmo, AbbVie said it represents a sizable commercial opportunity. However, sales are expected to ramp up gradually as commercial insurance and Medicare coverage expands, particularly from 2028.
Overall, AbbVie raised its 2026 revenue outlook by $200 million to approximately $67.8 billion.
ABBV’s Competition in the Neuroscience Space
Other major players in the neuroscience space include Biogen (BIIB - Free Report) and Johnson & Johnson (JNJ - Free Report) .
With revenues from its legacy multiple sclerosis portfolio continuing to decline, Biogen is increasingly focused on expanding its neuroscience business through newer therapies. Along with partner Eisai, Biogen markets Leqembi, one of the two FDA-approved treatments for Alzheimer's disease. The company also markets Zurzuvae, the first FDA-approved oral treatment for postpartum depression.
J&J's neuroscience business is anchored by the blockbuster depression therapy Spravato and long-acting antipsychotic Invega Sustenna. The company's acquisition of Intra-Cellular Therapies last year bolstered its portfolio with Caplyta, an approved treatment for schizophrenia and bipolar depression.
ABBV’s Price Performance, Valuation and Estimates
Year to date, shares of AbbVie have risen 29% compared with the industry’s nearly 27% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a slight discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 18.67 times forward earnings, lower than its industry’s average of 19.88 times.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2026 has risen slightly from $13.96 to $13.97, while the 2027 estimate has increased from $15.95 to $16.02 over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.